4//SEC Filing
Camac Fund, LP 4
Accession 0001209191-22-051650
CIK 0001841330other
Filed
Sep 29, 8:00 PM ET
Accepted
Sep 30, 4:36 PM ET
Size
11.7 KB
Accession
0001209191-22-051650
Insider Transaction Report
Form 4
Camac Partners, LLC
Other
Transactions
- Purchase
Common Stock
2022-09-29$1.16/sh+6,710$7,757→ 1,788,415 total(indirect: See footnote) - Purchase
Common Stock
2022-09-28$1.19/sh+57,647$68,542→ 1,781,705 total(indirect: See footnote)
Shahinian Eric
Other
Transactions
- Purchase
Common Stock
2022-09-28$1.19/sh+57,647$68,542→ 1,781,705 total(indirect: See footnote) - Purchase
Common Stock
2022-09-29$1.16/sh+6,710$7,757→ 1,788,415 total(indirect: See footnote)
Camac Fund, LP
Other
Transactions
- Purchase
Common Stock
2022-09-29$1.16/sh+6,710$7,757→ 1,788,415 total(indirect: See footnote) - Purchase
Common Stock
2022-09-28$1.19/sh+57,647$68,542→ 1,781,705 total(indirect: See footnote)
Camac Capital, LLC
Other
Transactions
- Purchase
Common Stock
2022-09-28$1.19/sh+57,647$68,542→ 1,781,705 total(indirect: See footnote) - Purchase
Common Stock
2022-09-29$1.16/sh+6,710$7,757→ 1,788,415 total(indirect: See footnote)
Footnotes (1)
- [F1]The shares are held by Camac Fund, LP. ("Camac Fund"). Eric Shahinian is the managing member of Camac Capital, LLC, which is the general partner of Camac Fund and the managing member of Camac Partners, LLC.
Documents
Issuer
Pasithea Therapeutics Corp.
CIK 0001841330
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001516478
Filing Metadata
- Form type
- 4
- Filed
- Sep 29, 8:00 PM ET
- Accepted
- Sep 30, 4:36 PM ET
- Size
- 11.7 KB